Value-based price for access (VBPA) may increase access of specialty drugs for patients.
Keith Bratti
Advertisement
Head of access & BDL strategy, Novartis Pharmaceuticals Corporation
Articles by Keith Bratti
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
2
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
3
Policy Whiplash in Pharma: Navigating Volatility with Strategic Clarity
4
Evolution of Biotech CFOs
5
